At a median follow-up of @ months , patients allocated to bevacizumab-pemetrexed had significantly improved PFS versus those on bevacizumab when measured from randomization -LSB- @ versus @ months , hazard ratio ( HR ) , @ , @ % confidence interval ( CI ) @-@ @ ) ; P < @ -RSB- .